T2C
2021-05-11
Wow
Novavax Reports Q1 Loss, Tops Revenue Estimates
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":199167504,"tweetId":"199167504","gmtCreate":1620691927908,"gmtModify":1634197134588,"author":{"id":3576917742134919,"idStr":"3576917742134919","authorId":3576917742134919,"authorIdStr":"3576917742134919","name":"T2C","avatar":"https://static.tigerbbs.com/18720cb4368721ede0a87e57a36d26df","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/199167504","repostId":2134659571,"repostType":4,"repost":{"id":"2134659571","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620683709,"share":"https://www.laohu8.com/m/news/2134659571?lang=&edition=full","pubTime":"2021-05-11 05:55","market":"us","language":"en","title":"Novavax Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2134659571","media":"Tiger Newspress","summary":"Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate","content":"<p>Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.</p><p>This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.</p><p>Over the last four quarters, the company has surpassed consensus EPS estimates just once.</p><p>Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.</p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p>Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.</p><p>Novavax shares fell more than 12% in after hour trading.<img src=\"https://static.tigerbbs.com/eac077132362fe2bc181215b07e0d9ac\" tg-width=\"1299\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><b>What's Next for Novavax?</b></p><p>While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p>Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.</p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Reports Q1 Loss, Tops Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Reports Q1 Loss, Tops Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-11 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.</p><p>This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.</p><p>Over the last four quarters, the company has surpassed consensus EPS estimates just once.</p><p>Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.</p><p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p><p>Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.</p><p>Novavax shares fell more than 12% in after hour trading.<img src=\"https://static.tigerbbs.com/eac077132362fe2bc181215b07e0d9ac\" tg-width=\"1299\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p><p><b>What's Next for Novavax?</b></p><p>While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p><p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p><p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p><p>Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p><p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.</p><p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2134659571","content_text":"Novavax (NVAX) came out with a quarterly loss of $3.05 per share versus the Zacks Consensus Estimate of a loss of $2.65. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -15.09%. A quarter ago, it was expected that this vaccine maker would post a loss of $1.53 per share when it actually produced a loss of $2.70, delivering a surprise of -76.47%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Novavax, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $447.23 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 53.23%. This compares to year-ago revenues of $3.38 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.Novavax shares have added about 57.8% since the beginning of the year versus the S&P 500's gain of 12.7%.Novavax shares fell more than 12% in after hour trading.What's Next for Novavax?While Novavax has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for Novavax was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.49 on $819.73 million in revenues for the coming quarter and $25.35 on $4.07 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 14% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.","news_type":1},"isVote":1,"tweetType":1,"viewCount":34,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/199167504"}
精彩评论